NovaPoint Capital LLC Grows Stock Holdings in Eli Lilly and Company $LLY

Key Points

• NovaPoint Capital LLC significantly increased its stake in Eli Lilly by 1,156.2% during Q2, now owning 3,329 shares valued at approximately $2.6 million.
• Several analysts have adjusted their price targets for Eli Lilly, with Cantor Fitzgerald reducing its target from $975 to $825, while the average consensus price target remains at $939.61.
• In its latest earnings report, Eli Lilly surpassed expectations with an EPS of $6.31, on revenues of $15.56 billion, a 37.6% increase year-over-year.

NovaPoint Capital LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 1,156.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,329 shares of the company's stock after acquiring an additional 3,064 shares during the period. NovaPoint Capital LLC's holdings in Eli Lilly and Company were worth $2,595,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Duquesne Family Office LLC boosted its position in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares in the last quarter. Corient IA LLC acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $570,000. LS Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the last quarter. Cutter Capital Management LP acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $14,866,000. Finally, Prism Advisors Inc. acquired a new position in Eli Lilly and Company in the first quarter valued at $207,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on LLY. Cantor Fitzgerald cut their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. JPMorgan Chase & Co. cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Guggenheim dropped their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Stock Up 1.4%

Shares of Eli Lilly and Company stock opened at $724.73 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business's fifty day moving average price is $734.15 and its two-hundred day moving average price is $767.20. The company has a market capitalization of $685.93 billion, a P/E ratio of 47.37, a PEG ratio of 0.99 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.